Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37285865

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2023 Jul 22
First author
Agarwal N

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2023 Jul 22;402(10398):266-267. doi: 10.1016/S0140-6736(23)01123-6.
    note
    Source null
    related pmid
    37285866
    relationship
    Comment in
  2. citation
    Nat Rev Urol. 2023 Aug;20(8):456. doi: 10.1038/s41585-023-00799-y.
    note
    Source null
    related pmid
    37430170
    relationship
    Comment in
  3. citation
    Lancet. 2023 Jul 22;402(10398):290. doi: 10.1016/S0140-6736(23)01482-4.
    note
    Source null
    related pmid
    37481270
    relationship
    Erratum in
  4. citation
    J Urol. 2023 Nov;210(5):822-824. doi: 10.1097/JU.0000000000003675.
    note
    Source null
    related pmid
    37622534
    relationship
    Comment in

Authors and identifiers

  1. name
    Agarwal N
    type
    Author
  2. name
    Azad AA
    type
    Author
  3. name
    Carles J
    type
    Author
  4. name
    Fay AP
    type
    Author
  5. name
    Matsubara N
    type
    Author
  6. name
    Heinrich D
    type
    Author
  7. name
    Szczylik C
    type
    Author
  8. name
    De Giorgi U
    type
    Author
  9. name
    Young Joung J
    type
    Author
  10. name
    Fong PCC
    type
    Author
  11. name
    Voog E
    type
    Author
  12. name
    Jones RJ
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Agarwal N
    type
    Author
  2. name
    Azad AA
    type
    Author
  3. name
    Carles J
    type
    Author
  4. name
    Fay AP
    type
    Author
  5. name
    Matsubara N
    type
    Author
  6. name
    Heinrich D
    type
    Author
  7. name
    Szczylik C
    type
    Author
  8. name
    De Giorgi U
    type
    Author
  9. name
    Young Joung J
    type
    Author
  10. name
    Fong PCC
    type
    Author
  11. name
    Voog E
    type
    Author
  12. name
    Jones RJ
    type
    Author
bibliography ids
  1. nci-bib-0f20ff440f136cb7b6ddc1e8
book metadata
content sha256
4d3666a704bad171a0162c99ef94c9ed5abc1c49b65b32ee530be7d3194efb7c
document type
citation
dois
  1. 10.1016/S0140-6736(23)01055-3
electronic publication date
display
2023 Jun 4
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:37285865
immutable id
pubmed:37285865@4d3666a704bad171a0162c99ef94c9ed5abc1c49b65b32ee530be7d3194efb7c
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10398
name
Lancet (London, England)
nlm unique id
2985213R
pages
291-303
volume
402
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2023 Jul 22;402(10398):266-267. doi: 10.1016/S0140-6736(23)01123-6.
    note
    Source null
    related pmid
    37285866
    relationship
    Comment in
  2. citation
    Nat Rev Urol. 2023 Aug;20(8):456. doi: 10.1038/s41585-023-00799-y.
    note
    Source null
    related pmid
    37430170
    relationship
    Comment in
  3. citation
    Lancet. 2023 Jul 22;402(10398):290. doi: 10.1016/S0140-6736(23)01482-4.
    note
    Source null
    related pmid
    37481270
    relationship
    Erratum in
  4. citation
    J Urol. 2023 Nov;210(5):822-824. doi: 10.1097/JU.0000000000003675.
    note
    Source null
    related pmid
    37622534
    relationship
    Comment in
outcomes validated
false
pmid
37285865
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
b093ef67b5396988caa6d555b0233b335889b98ea5d2a8fe7478390ecc853729
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 Jul 22
precision
day
year
2023
publication types
  1. Randomized Controlled Trial
  2. Clinical Trial, Phase III
  3. Journal Article
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37285865/
title
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice